An anti-NRP1 mAb, MNRP1685A, is currently in Phase I clinical trials for patients with progressive solid tumors and has been shown to reduce tumor burden significantly via blockade of the VEGF pathway. This evidence concerns the gene VEGFA and neoplasm.